Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells.
AffiliationClinical and Experimental Pharmacology Group, Manchester Cancer Research Centre, Cancer Research UK Manchester Institute, University of Manchester
MetadataShow full item record
AbstractThe monocarboxylate transporter-1 (MCT1) represents a novel target in rational anticancer drug design while AZD3965 was developed as an inhibitor of this transporter and is undergoing Phase I clinical trials ( http://www.clinicaltrials.gov/show/NCT01791595 ). We describe the optimisation of an immunofluorescence (IF) method for determination of MCT1 and MCT4 in circulating tumour cells (CTC) as potential prognostic and predictive biomarkers of AZD3965 in cancer patients.
CitationOptimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells. 2015, 15:387 BMC Cancer